Passer au contenu principal

Nadia Bambace

Nadia Bambace

Assistant Professor


Université de Montréal

Research Axes

Clinical research

Contact information

A medical expert in acute leukemia for the Institut national d’excellence en santé et en services sociaux (INESSS) and a hematologist at Hôpital Maisonneuve-Rosemont, Dr. Nadia Bambace is also an assistant professor with the Faculty of Medicine of Université de Montréal. Her research interests include advancing knowledge and therapies for leukemia patients, reducing post-transplant stem cell complications, and improving patient quality of life.

Research Unit

This research unit is interested in clinical and basic research in cell therapy with the goal of improving care, overall survival rates, and quality of life post-transplant.

Ongoing studies include umbilical cord blood stem cells expanded with UM171 to treat leukemia, myelodysplastic syndrome and myeloma. This experimental treatment is sometimes the last resort for patients and offers them an additional chance of survival.

The unit is also involved in studies to reduce the current complications from transplantation, such as graft-versus-host disease (GVHD), thrombotic microangiopathy, and viral respiratory diseases, which can significantly affect patients’ quality of life. The goal of reducing the occurrence or severity of these side effects of bone marrow transplantation is to improve overall quality of life.

Our work on paroxysmal nocturnal hemoglobinuria (PNH), a rare disease for which treatments are currently limited, provides patients with treatment options they would not otherwise have.

Our approach is to give patients treatment options that can increase their chance of survival, quality of life, and quality of care.

  • Dumont-Lagacé M, Li Q, Tanguay M, Chagraoui J, Kientega T, Cardin GB, Brasey A, Trofimov A, Carli C, Ahmad I, Bambace NM, Bernard L, Kiss TL, Roy J, Roy DC, Lemieux S, Perreault C, Rodier F, Dufresne SF, Busque L, Lachance S, Sauvageau G, Cohen S, Delisle JS. UM171-expanded cord blood transplants support robust T cell reconstitution with low rates of severe infections. Biol Blood Marrow Transplant. 2020 Oct 3:S1083-8791(20)30624-8. doi: 10.1016/j.bbmt.2020.09.031.
  • LeBlanc R, Claveau JS, Ahmad I, Delisle JS, Bambace N, Bernard L, Cohen S, Kiss T, Lachance S, Landais S, Roy DC, Sauvageau G, Roy J. Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. Clin Transplant. 2020 Sep 27:e14099. doi: 10.1111/ctr.14099.
  • Claveau JS, Cohen S, Ahmad I, Delisle JS, Kiss T, Lachance S, Sauvageau G, Busque L, Brito RM, Bambace N, Bernard L, Claude Roy D, Roy J. Single UM171-expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors. Single UM171-expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors. Eur J Haematol. 2020 Aug 4. doi: 10.1111/ejh.13504._


  • Advanced diploma (fellowship) in hematopoietic stem cell transplantation

    Université de Montréal

  • Specialization in hematology-oncology

    University of Vermont

  • Specialization in internal medicine

    University of Vermont

  • Doctor of Medicine

    Université de Montréal


  • 2013 “Les attentionnés” Award  (Hôpital Maisonneuve-Rosemont)
  • 2008 Frank L. Babbott, MD Memorial Award for Clinical Excellence and Idealism in Medicine  (University of Vermont)
  • 2008 Harriet P. Dustan Award for Most Outstanding and Promising Research Project  (University of Vermont)